Pfizer and biontech receive positive chmp opinion for comirnaty® in children 5 to under 12 years of age in the european union

New york and mainz, germany, november 25 , 2021— pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) issued a positive opinion on the administration of the companies' covid-19 vaccine comirnaty® in children 5 to under 12 years of age. the european commission (ec) will review the chmp recommendation and is expected to make a final decision on a variation to the conditional marketing authorization in the near future. if the ec grants the variation regarding a vaccination in this age group, the decision will be immediately applicable to all 27 eu member states. if approved, comirnaty will be the first covid-19 vaccine authorized in the european union for individuals 5 to under 12 years of age.
BNTX Ratings Summary
BNTX Quant Ranking